Switching from dulaglutide to tirzepatide improves HbA1c reduction in type 2 diabetes

Published Date: 05 Apr 2025

For patients with inadequately controlled type 2 diabetes receiving dulaglutide, switching to tirzepatide is associated with additional hemoglobin A1c (HbA1c) reduction and weight loss compared with escalating treatment with ...

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Remote monitoring can improve recovery from cancer surgery

2.

Intractable cancers may respond better to treatment when using new radiation and high-performance computing.

3.

A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials

4.

Conditional EU Nod for Weekly Pill in Pediatric Glioma

5.

high response rate when using a bispecific antibody to treat R/R multiple myeloma.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot